Home » Stocks » NVTA

Invitae Corporation (NVTA)

Stock Price: $46.85 USD -3.21 (-6.41%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $50.06 +3.21 (6.85%) Nov 27, 5:00 PM

Stock Price Chart

Key Info

Market Cap 8.28B
Revenue (ttm) 245.45M
Net Income (ttm) -444.74M
Shares Out 176.70M
EPS (ttm) -3.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $46.85
Previous Close $50.06
Change ($) -3.21
Change (%) -6.41%
Day's Open 48.41
Day's Range 46.85 - 50.73
Day's Volume 1,966,734
52-Week Range 7.64 - 53.31

More Stats

Market Cap 8.28B
Enterprise Value 8.24B
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 176.70M
Float n/a
EPS (basic) -3.86
EPS (diluted) -3.91
FCF / Share -1.91
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 26.08M
Short Ratio 9.67
Short % of Float n/a
Beta 2.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 33.73
PB Ratio 21.24
Revenue 245.45M
Operating Income -399.73M
Net Income -444.74M
Free Cash Flow -252.69M
Net Cash 36.04M
Net Cash / Share 0.20
Gross Margin 40.22%
Operating Margin -162.85%
Profit Margin -181.20%
FCF Margin -102.95%
ROA -25.68%
ROE -108.42%
ROIC -72.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 2
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$46.31*
(-1.15% downside)
Low
41.0
Current: $46.85
High
50.0
Target: 46.31
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue21714868.2225.058.381.600.15-
Revenue Growth46.8%116.5%172.36%198.97%422.32%983.78%--
Gross Profit98.7267.5918.08-2.83-8.15-4.02-0.52-
Operating Income-244-123-121-100-89.48-47.35-24.75-8.56
Net Income-242-129-123-100-89.78-47.49-24.99-8.60
Shares Outstanding90.8666.7546.5133.1828.210.850.690.64
Earnings Per Share-2.66-1.94-2.65-3.02-3.18-56.14-36.13-14.18
Operating Cash Flow-145-92.22-97.98-76.32-80.66-42.44-23.03-9.15
Capital Expenditures-20.05-5.97-6.68-11.63-6.46-6.69-4.52-0.77
Free Cash Flow-165-98.19-105-87.94-87.12-49.13-27.55-9.92
Cash & Equivalents39813270.0797.3213210743.1921.86
Total Debt31977.7944.5013.6810.203.542.001.22
Net Cash / Debt79.1854.1025.5783.6412210441.1920.65
Assets78228321113115712953.1025.97
Liabilities40212189.2831.5818.3010.053.811.98
Book Value38016212299.07138-83.58-37.28-12.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Invitae Corporation
Country United States
Employees 1,900
CEO Sean Emerson George

Stock Information

Ticker Symbol NVTA
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: NVTA
IPO Date February 12, 2015

Description

Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.